Foresight diagnostics series#
We recently emerged from stealth mode when we announced our Series A financing, and this has catalyzed a lot of rapid growth within the organization, as well as an influx of clinical collaborations with pharmaceutical and academic partners. Seeing how our mission transforms cancer patient treatments for the better gets us out of bed in the morning. How does your culture shape what your company or organization produces or offers?Ī: We are a fast-paced and tight-knit startup that believes in our mission and technology. Over the last year, we have built a world-class team of investors, board members and advisors who are all former life sciences executives and operators.
I founded the company in 2020 along with three Stanford University faculty members who have a long history of developing cutting-edge cancer diagnostic technologies. Our goal is to enable better personalized treatment approaches for cancer patients. Q: Tell us about your company or organization.Ī: We are a cancer diagnostics company and CLIA-registered laboratory located on the Anschutz Medical Campus in Aurora. Colorado members of the Foresight Diagnostics team outside of Fitzsimons Innovation Community in 2021 Foresight does this by using the world’s most sensitive cancer surveillance technology to detect cancer relapse up to 100 days sooner than current testing methods.ĬBSA President and CEO Jennifer Jones Paton asked Jake Chabon, Ph.D., CEO, CSO, and Co-Founder of Foresight Diagnostics, CBSA’s Key Questions for Life Sciences Innovators.
The Foresight team can identify patients that are cured of lymphoma during treatment, eliminating unnecessary chemotherapy and dramatically improving quality of life. Foresight Diagnostics, an emerging leader in blood-based lymphoma disease monitoring, is transforming patient care with groundbreaking cancer surveillance technology.
0 kommentar(er)
